Neoplasm Clinical Trial
Official title:
Clinical Evaluation of a Laser Heated, Fiberoptic-Coupled Radiation Dose Verification System
We propose to determine the response of a newly developed laser heated, vycor glass
fiberoptic radiation dosimetry system to ionizing radiation in a clinical radiotherapy
environment. Present systems measure only total dose or have limitations, such as
instability, non-linearity, excessive size or a decoupled measurement system, making them
unsuitable in a variety of clinical applications. This fiberoptic coupled dosimetry system
is a new and innovative technology application which allows on-line measurement of
instantaneous dose rate and total dose never before achievable. It offers a clear advantage
in patient treatment delivery, allowing on-line corrections essential to a new generation of
radiotherapy treatment machines with development of beam intensity modulation as an adjunct
to 3D conformal therapy. It also has the advantage of submillimeter size and is minimally
invasive, making it ideal for brachytherapy.
This system has the potential for stable, accurate, reproducible, clinically feasible
measurements of total dose and dose rate. The output of this system will be measured under
various clinical conditions encountered in a clinical setting and compared against existing
thermolumeniscent and diode dosimetry standards. Initial measurements will use a tissue
equivalent phantom for depth dose and accuracy measurements. Additional studies will include
dosimetric measurements of routine clinical treatment setups on patients receiving
therapeutic irradiation.
We propose to determine the response of a newly developed laser heated, vycor glass
fiberoptic radiation dosimetry system to ionizing radiation in a clinical radiotherapy
environment. Present systems measure only total dose or have limitations, such as
instability, non-linearity, excessive size or a decoupled measurement system, making them
unsuitable in a variety of clinical applications. This fiberoptic coupled dosimetry system
is a new and innovative technology application which allows on-line measurement of
instantaneous dose rate and total dose never before achievable. It offers a clear advantage
in patient treatment delivery, allowing on-line corrections essential to a new generation of
radiotherapy treatment machines with development of beam intensity modulation as an adjunct
to 3D conformal therapy. It also has the advantage of submillimeter size and is minimally
invasive, making it ideal for brachytherapy.
This system has the potential for stable, accurate, reproducible, clinically feasible
measurements of total dose and dose rate. The output of this system will be measured under
various clinical conditions encountered in a clinical setting and compared against existing
thermolumeniscent and diode dosimetry standards. Initial measurements will use a tissue
equivalent phantom for depth dose and accuracy measurements. Additional studies will include
dosimetric measurements of routine clinical treatment setups on patients receiving
therapeutic irradiation.
;
Endpoint Classification: Safety Study, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT00199836 -
A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer.
|
Phase 1 | |
Completed |
NCT01672944 -
Evaluating Biobanking Educational Tools
|
N/A | |
Not yet recruiting |
NCT02226289 -
Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment
|
Phase 2 | |
Completed |
NCT02747342 -
A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer
|
Phase 1 | |
Completed |
NCT02746185 -
Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban
|
Phase 3 | |
Completed |
NCT02759640 -
A Phase I Trial of HS-10241 in Solid Tumors
|
Phase 1 | |
Completed |
NCT02536586 -
A Study of LY3023414 in Japanese Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02309164 -
The Use of Acupuncture for Treatment of Chemotherapy-induced Peripheral Neuropathy (CIPN).
|
N/A | |
Completed |
NCT02394821 -
Odor Management in Fungating Wounds Comparing Metronidazole and Polihexanide
|
Phase 3 | |
Completed |
NCT01457196 -
Development of a Tumor Molecular Analyses Program and Its Use to Support Treatment Decisions
|
N/A | |
Completed |
NCT00143533 -
Prevention of Diarrhea in Patients Taking IV Irinotecan for Relapsed or Difficult to Treat Pediatric Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05450562 -
Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00001835 -
Oxaliplatin in Cancer Patients With Impaired Kidney Function
|
Phase 1 | |
Completed |
NCT00001341 -
A Phase I Trial of ZD1694 (TOMUDEX), an Inhibitor of Thymidylate Synthase, in Pediatric Patients With Advanced Neoplastic Disease
|
Phase 1 | |
Completed |
NCT01425008 -
Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma
|
Phase 1 | |
Recruiting |
NCT05101798 -
The Role of 5-Aminolevulinic Acid Fluorescence-Guided Surgery in Head and Neck Cancers: a Pilot Trial
|
Phase 2 | |
Completed |
NCT01920061 -
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
|
Phase 1 | |
Terminated |
NCT03251924 -
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02851706 -
Natural History of and Specimen Banking for People With Tumors of the Central Nervous System
|